PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.
Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.
A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Autologous stem cell therapy may offer hope for patients with COPD. But some say caution is necessary.
CVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.
Here are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.
PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.
An eye-opening study by Precision for Value assesses cancer value frameworks.
An Avalere study has interesting findings about payer acceptance of biosimilars.